PD-L1 SNPs 作为生物标志物，可预测晚期 NSCLC 患者接受免疫检查点抑制剂治疗的获益情况。
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
机构信息
Medical Oncology Unit, University Hospital of Parma, Parma, Italy.
Department of Medicine & Surgery, University of Parma.
出版信息
Tumori. 2022 Feb;108(1):47-55. doi: 10.1177/03008916211014954. Epub 2021 May 18.
OBJECTIVE
To investigate the role of (programmed death-1), and (programmed death-ligand 1) single nucleotide polymorphisms (SNPs) in predicting clinical outcome of patients with advanced non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors (ICIs).
METHODS
A total of 166 consecutive patients were included. We correlated SNPs with clinical benefit, progression-free survival, time to treatment failure, and overall survival and evaluated the incidence of SNPs in nonresponder and long clinical benefit groups.
RESULTS
Considering the entire cohort, no correlation was found between SNPs and clinical outcome; however, rs4143815 SNP and the long clinical benefit group showed a statistically significant association ( = 0.02). The nonresponder cohort displayed distinctive haplotype ( = 0.05).
CONCLUSION
SNPs seem to be marginally involved in predicting clinical outcome of NSCLC treated with ICI, but further investigations are required.
目的
探讨程序性死亡受体-1（PD-1）和程序性死亡受体配体 1（PD-L1）单核苷酸多态性（SNPs）在预测接受免疫检查点抑制剂（ICI）治疗的晚期非小细胞肺癌（NSCLC）患者临床结局中的作用。
方法
共纳入 166 例连续患者。我们将 SNPs 与临床获益、无进展生存期、治疗失败时间和总生存期相关联，并评估了 SNPs 在无应答者和长临床获益组中的发生率。
结果
考虑到整个队列，SNP 与临床结局之间未发现相关性；然而，rs4143815 SNP 与长临床获益组显示出统计学显著关联（=0.02）。无应答者队列显示出独特的单倍型（=0.05）。
结论
SNP 似乎与预测接受 ICI 治疗的 NSCLC 的临床结局有一定的相关性，但需要进一步的研究。
Zotero 插件